Figure 3 | Blood Cancer Journal

Figure 3

From: The role of the proteasome in AML

Figure 3

Structures of key proteasome inhibitors. Chemical structures of select clinical and investigational proteasome inhibitors: the dipeptide boronic acid bortezomib, tetrapeptide epoxyketone carfilzomib and tripeptide epoxyketone PR-957.

Back to article page